• Home
  • » 
  • Reports
  • » 
  • Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights | Industry Analysis | Pipeline Review |

Chronic Kidney Diseases

Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

  • Lowest Price Guaranteed From USD 2,349

  • Published
    November 2018

  • Pages
    164

  • View Count
    8197

  • Buy Now

Example Insights

Report Description

Chronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine and foamy urine) are rarely observed until kidney function has declined by 75%. It is worth highlighting that over 90% of the patients suffering from reduced kidney function are unaware of their medical condition.In the US, 15% of adults are reported to be suffering from mild or severe forms of CKD.In fact, the mean global prevalence of CKD, across all five stages of the disease, is estimated to be 13.4%. Limited availability of epidemiological data, lack of awareness, late diagnosis and inappropriate / incorrect treatment are some of the factors responsible for elevating disease incidence. It is also worth noting that developed nations spend over 2-3% of their annual healthcare budget on the treatment of end-stage renal disease (ESRD); however, the economic burden associated with milder forms of CKD is almost double the total costs incurred in the treatment of ESRD. Further, in the US, the disease has been estimated to incur combined direct and indirect costs ranging of USD 14,545 per patient.

Existing therapeutic options have already been proven to be inadequate in containing the progression of the disease and its symptoms in the long term. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease modifying pharmacological interventions and therapies that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital funding in order to expedite the development of potential therapeutic options for better disease management.

 

Scope of the Report

The “Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights” report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of chronic kidney disease. Figure 1 summarizes the scope of the report and the specific modules that have been covered in detail in the document.

Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), treatment type (disease modifying agent or drugs offering symptomatic relief), mechanism of action, and route of administration of the drugs being developed for the treatment of chronic kidney disease.
  • An in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a heptagon representation, highlighting the distribution of the marketed and development stage molecules based on the target clinical condition, [B] a 2X2 grid analysis, representing the distribution of drug candidates across various disease indications, dosing frequencies and stages of development, and [C] a diagrammatic representation of the regional landscape of industry players involved in the development of drugs in this domain, distributed based on the location of their headquarters.
  • An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), taking into consideration size of enrolled patient population (for the trial in the highest phase of development), route of administration, treatment type (disease modifying agent and drugs offering symptomatic relief) and dosing frequency (for quantifying clinical attractiveness), and target patient population, expected launch date and size of developer company (for quantifying commercial attractiveness).
  • An analysis highlighting the key unmet needs across chronic kidney disease, featuring insights generated from real-time data on unmet needs as identified from social media posts, recent publications, patient blogs and the views of key opinion leaders expressed on online platforms.
  • An insightful competitive analysis, highlighting the key players in the domain on the basis of the strength of their respective development portfolios, taking into account company size and the stage of development of lead molecules in their respective pipelines.
  • A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and commercialization agreements, manufacturing agreements and others
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered from secondary sources. The opinions and insights presented in this study were influenced by inputs of several key players in this domain. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Oultine

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the chronic kidney disease market in the long term.

Chapter 3 provides an introduction to chronic kidney disease and its associated comorbidities. It features a detailed discussion on the development, symptoms and stages of the condition, factors influencing disease progression and the various treatment regimens that are available in the market. It also includes a discussion on the epidemiology of the disease and the associated economic burden across various regions.

Chapter 4 includes information on over 160 molecules that are currently approved / under development for therapeutic use. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (clinical, preclinical / discovery stage), type of molecule (small molecule or biologic), treatment type (disease modifying agent or drugs offering symptomatic relief), mechanism of action, and route of administration of the drug candidates. In addition, it presents certain key insights derived from the study, which include a heptagon representation highlighting the distribution of the marketed and pipeline molecules based on different clinical indications. The chapter includes a comprehensive 2X2 grid analysis, representing the distribution of drug candidates across various indications, dosing frequencies and stages of development. Additionally, the chapter features a regional landscape of developers engaged in this domain, distributed on the basis of the location of their headquarters.

Chapter 5 features an analysis of the clinical and commercial attractiveness of the drugs designed for the treatment of CKD and its associated comorbidities. The drugs are plotted on a 2X2 matrix, with clinical attractiveness (abscissa) and commercial attractiveness (ordinate) as the two axes. The clinical attractiveness of a drug is determined by sample size of its trial (highest phase), route of administration, treatment type (disease modifying agent and drugs offering symptomatic relief) and dosage frequency. The commercial attractiveness of a drug is determined by the target population size, expected launch date and the company size.

Chapter 6 highlights the key unmet needs associated with the management and treatment of chronic kidney disease. The chapter provides detailed analysis of unmet needs that were identified from views expressed by patients / experts across different platforms, such as social media posts, recent publications and patient blogs, and the inputs of key opinion leaders at conferences / symposiums. The chapter presents an insightful sentiment analysis and word cloud analysis, summarizing the opinions expressed across public portals.

Chapter 7 presents an analysis of the competitive landscape of companies involved in the development of novel therapeutics for the treatment of chronic kidney disease. It is based on the number of molecules in the pipelines of different players (taking into consideration the current status of development) and company size (in terms of number of employees). In this analysis, companies across different regions (North America, Europe and Asia-Pacific) were plotted on 2X2 matrices, having company pipeline strengthas the ordinate and company size as the abscissa.

Chapter 8 provides an analysis of KOLs in the field of chronic kidney disease. It features a comprehensive list of principal investigators of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also features a comparative analysis, highlighting those KOLs who have relatively more experience in this domain.

Chapter 9 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including product development and commercialization, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers / acquisitions and clinical trial collaborations) and the most common forms of deals / agreements that have been established between 2015 to 2018.

Chapter 10 presents details on various investments received by companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, in the period between 2010 and July 2018, highlighting the growing interest of the venture capital community and other strategic investors in this market.

Chapter 11 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 12 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. An Overview of Chronic Kidney Diseases
3.1.1. Medical Conditions Associated with Chronic Kidney Diseases
3.1.1.1. Alport Syndrome
3.1.1.2. Diabetic Nephropathy
3.1.1.3. Focal Segmental Glomerulosclerosis
3.1.1.4. Glomerulonephritis
3.1.1.5. Nephrotic Syndrome
3.1.1.6. Polycystic Kidney Disease
3.1.1.7. Hypertensive Kidney Disease
3.1.1.8. Pyelonephritis
3.1.2. Stages of Chronic Kidney Disease
3.1.3. Symptoms Associated with Chronic Kidney Disease
3.1.4. Diagnosis of Chronic Kidney Disease
3.1.5. Treatment Options for Chronic Kidney Disease
3.1.5.1. Therapeutics
3.1.5.2. Other Modalities
3.1.6. Kidney Transplant and Implications
4. PIPELINE REVIEW: MARKETED AND DEVELOPMENT DRUGS
4.1. Chapter Overview
4.2. Drugs for Chronic Kidney Disease: Marketed and Development Pipeline
4.3. Chronic Kidney Disease: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Type of Treatment
4.3.4. Analysis by Type of Therapy
4.3.5. Analysis by Type of Receptor
4.3.6. Analysis by Route of Administration
4.3.7. Analysis by Target Therapeutic Indication(s)
4.3.8. Analysis by Size of Developer
4.3.9. Analysis of Leading Developers
4.3.10. Analysis by Size and Location of the Players
4.3.11. Heptagon Representation: Distribution by Target Therapeutic Indication and Phase of Development
4.3.12. Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
4.3.13. Geographical Landscape

5. PRODUCT CLINICAL COMMERCIAL ATTRACTIVENESS
5.1. Chapter Overview
5.2. Methodology
5.2.1. Assumptions and Key Parameters
5.3. Affiliated Insights
5.3.1. Clinical and Commercial Attractiveness Analysis: Anemia
5.3.2. Clinical and Commercial Attractiveness Analysis: Diabetic Nephropathy and Nephrotic Syndrome
5.3.3. Clinical and Commercial Attractiveness Analysis: Focal Segmental Glomerulosclerosis
5.3.4. Clinical and Commercial Attractiveness Analysis: Lupus Nephritis and Pyelonephritis
5.3.5. Clinical and Commercial Attractiveness Analysis: IgA Nephropathy
5.3.6. Clinical and Commercial Attractiveness Analysis: CKD (Indication Unspecified)

6. CHRONIC KIDNEY DISEASE: UNMET NEEDS ANALYSIS
6.1. Chapter Overview
6.2. Unmet Needs Analysis in Chronic Kidney Disease Market
6.2.1. Analysis of Data from Patient Blogs
6.2.1.1. Methodology
6.2.1.2. Key Insights
6.2.2. Analysis of Data from Published Literature
6.2.2.1. Methodology
6.2.2.2. Key Insights
6.2.3. Analysis of Data from Social Media Platforms
6.2.3.1. Methodology
6.2.3.2. Key Insights
6.2.4. Expert opinions
6.2.4.1. Titte Srinivas, Intermountain Medical Centre
6.2.4.2. Brian Clement, Hippocrates Health Institute
6.2.4.3. Frank Brennan, Palliative Care Physician
6.2.4.4. Sarah Brook, Renal Dietitian, Salford Royal NHS Foundation Trust
6.2.4.5. Joseph Selvanayagam, Medical Researcher, Flinders University
6.2.4.6. Vanessa Rojas-Bautista, UC Irvine Health
6.2.5. Summary of Key Unmet Needs in Chronic Kidney Disease

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.1.1. Assumptions and Key Parameters
7.2. Company Competitiveness Analysis: Key Insights
7.2.1. Key Players: North America
7.2.2. Key Players: Europe
7.2.3. Key Players: Asia Pacific

8. KOL ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.4. Prominent Key Opinion Leaders
8.4.1. Geographical Distribution
8.5. Most Active Key Opinion Leaders
8.5.1. KOL Profiles: Dennis Andress
8.5.2. KOL Profile: Geoffrey A Block
8.5.3. KOL Profile: Glenn Chertow
8.5.4. KOL Profile: Steven Fishbane

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Therapeutics for Chronic Kidney Disease: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Chronic Kidney Disease Market: Funding and Investment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Most Active Players
10.3.5. Analysis by Most Active Investors
10.4. Concluding Remarks

11. APPENDIX 1: TABULATED DATA
11.1. Chapter Overview
11.2. Key Takeaways

12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 1.1 Chronic Kidney Disease: Scope and Competitive Insights 
Figure 3.1 Epidemiology of Chronic Kidney Disease 
Figure 3.2 Factors Involved in the Progression of Diabetic Nephropathy 
Figure 3.3 Symptoms of Chronic Kidney Disease
Figure 3.4 Diagnostic Techniques for Chronic Kidney Disease
Figure 3.5 Treatment Options for Chronic Kidney Disease
Figure 3.6 ACE Inhibitors: Mechanism of Action
Figure 3.7 Statins: Mechanism of Action
Figure 3.8 Loop Diuretics: Mechanism of Action
Figure 3.9 Thiazide Diuretics: Mechanism of Action
Figure 3.10 Complications Associated with Kidney Transplants 
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Molecule
Figure 4.3 Pipeline Analysis: Distribution by Type of Treatment
Figure 4.4 Pipeline Analysis: Distribution by Type of Therapy 
Figure 4.5 Pipeline Analysis: Distribution by Type of Receptor
Figure 4.6 Pipeline Analysis: Distribution by Route of Administration
Figure 4.7 Pipeline Analysis: Distribution by Target Therapeutic Indication(s)
Figure 4.8 Pipeline Analysis: Distribution by Size of Employee Base of Developer
Figure 4.9 Pipeline Analysis: Leading Players 
Figure 4.10 Pipeline Analysis: Distribution by Size and Location 
Figure 4.11 Heptagon Representation: Distribution by Target Therapeutic Indication and Phase of Development
Figure 4.12 Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
Figure 4.13 Geographical Landscape
Figure 5.1 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Anemia
Figure 5.2 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Diabetic Nephropathy and Nephrotic Syndrome
Figure 5.3 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Focal Segmental Glomerulosclerosis
Figure 5.4 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Lupus Nephritis and Pyelonephritis 
Figure 5.5 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for IgA Nephropathy
Figure 5.6 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for CKD (Indication Unspecified)
Figure 6.1 Unmet Needs Analysis: Overview of the Methodology
Figure 6.2 Unmet Needs in the Chronic Kidney Disease Market: Word Cloud Analysis of Data from Patient Blogs
Figure 6.3 Chronic Kidney Disease: Unmet Needs Highlighted in Published Literature
Figure 6.4 Unmet Needs in Chronic Kidney Disease: Social Media Platforms, Sentiment Analysis 
Figure 6.5 Unmet Needs in Chronic Kidney Disease: Word Cloud Analysis of Data from Social Media Tweets
Figure 6.6 Unmet Needs in Chronic Kidney Disease, Social Media Analysis: Indication Specific Word Clouds 
Figure 6.7 Unmet Needs in Chronic Kidney Disease, Social Media Analysis: Indication Specific Word Clouds
Figure 6.8 Chronic Kidney Disease: Key Unmet Needs
Figure 7.1 Company Competitiveness Analysis: North America
Figure 7.2 Company Competitiveness Analysis: Europe
Figure 7.3 Company Competitiveness Analysis: Asia Pacific
Figure 8.1 KOL Analysis: Dot-Plot of Principal Investigators 
Figure 8.2 KOL Analysis: Geographical Location of Principal Investigators 
Figure 8.3 KOL Analysis: Most Active Key Opinion Leaders
Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2018
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Most Active Players
Figure 9.4 Partnerships and Collaborations: Regional Distribution
Figure 9.5 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 Funding and Investment Analysis: Cumulative Number of Instances, 2010-2018
Figure 10.2 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2018 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution by Type of Funding, 2010-2018
Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Figure 10.5 Chronic Kidney Disease: Summary of Investments, January 2010-July 2018 (USD Million)
Figure 10.6 Funding and Investment Analysis: Most Active Players
Figure 10.7 Funding and Investment Analysis: Most Active Investors
Figure 10.8 Funding and Investment Summary

List Of Tables

Table 3.1 Indicative Values of Focal Segmental Glomerulosclerosis
Table 3.2 Stages of Chronic Kidney Disease
Table 4.1 Chronic Kidney Disease: Marketed and Development Pipeline
Table 8.1 KOL Analysis: List of Principal Investigators
Table 8.2 KOL Analysis: List of Universities and Hospitals
Table 8.3 KOL Analysis: Scoring System
Table 8.4 KOL Profile: Dennis Andress, Clinical Trials
Table 8.5 KOL Profile: Dennis Andress, Published Literature
Table 8.6 KOL Profile: Geoffrey A Block, Clinical Trials
Table 8.7 KOL Profile: Geoffrey A Block, Published Literature
Table 8.8 KOL Profile: Glenn Chertow, Clinical Trials
Table 8.9 KOL Profile: Glenn Chertow, Published Literature
Table 8.10 KOL Profile: Steven Fishbane, Clinical Trials
Table 8.11 KOL Profile: Steven Fishbane, Published Literature
Table 9.1 Novel Therapeutics for Chronic Kidney Disease: Partnerships and Collaborations, 2015-2018
Table 10.1 Chronic Kidney Disease Market: Funding and Investments, 2010-2018
Table 10.2 Funding and Investment Analysis: Summary of Investments
Table 11.1 Chronic Kidney Disease: Summary of the Competitive Insights
Table 12.1 Epidemiology of Chronic Kidney Disease
Table 12.2 Pipeline Analysis: Distribution by Phase of Development
Table 12.3 Pipeline Analysis: Distribution by Type of Molecule
Table 12.4 Pipeline Analysis: Distribution by Type of Treatment
Table 12.5 Pipeline Analysis: Distribution by Type of Therapy 
Table 12.6 Pipeline Analysis: Distribution by Type of Receptor 
Table 12.7 Pipeline Analysis: Distribution by Route of Administration
Table 12.8 Pipeline Analysis: Distribution by Target Therapeutic Indication(s)
Table 12.9 Pipeline Analysis: Distribution by Size of Developer 
Table 12.10 Pipeline Analysis: Leading Players
Table 12.11 Pipeline Analysis: Distribution by Size and Location of the Players 
Table 12.12 Heptagon Representation: Distribution by Type of Indication and Development Stage
Table 12.13 Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
Table 12.14 Geographical Landscape Analysis: Distribution by Developers and their Headquarters 
Table 12.15 Unmet Needs in Chronic Kidney Disease: Needs Highlighted in Published Literature
Table 12.16 Unmet Needs in Chronic Kidney Disease: Social Media Platforms, Sentiment Analysis
Table 12.17 Unmet Needs in Chronic Kidney Disease, Social Media Analysis: Indication Specific Tweets
Table 12.18 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2018
Table 12.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.20 Partnerships and Collaborations: Most Active Players
Table 12.21 Partnerships and Collaborations: Regional Distribution
Table 12.22 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 12.23 Funding and Investment Analysis: Cumulative Number of Instances, 2010-2018
Table 12.24 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2018 (USD Million)
Table 12.25 Funding and Investment Analysis: Distribution by Type of Funding, 2010-2018
Table 12.26 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Table 12.27 Chronic Kidney Disease: Summary of Investments, January 2010-July 2018 (USD Million)
Table 12.28 Funding and Investment Analysis: Most Active Players
Table 12.29 Funding and Investment Analysis: Most Active Investors
Table 12.30 Funding and Investment Summary

List of Companies

The following companies and organizations have been mentioned in the report:

  1. Aarhus University
  2. Achillion Pharmaceuticals
  3. Advantech Capital
  4. AJU IB Investment
  5. Akebia Therapeutics
  6. Albany College of Pharmacy and Health Sciences
  7. Alexandria Venture Investments
  8. Alexion Pharmaceuticals
  9. Algomedix
  10. Allegheny Financial Group
  11. Amgen
  12. Amyndas Pharmaceuticals
  13. Angion Biomedica
  14. Anthera Pharmaceuticals
  15. apceth Biopharma
  16. Apellis Pharmaceuticals
  17. AptaBio Therapeutics
  18. Apollo Hospitals
  19. Ardelyx
  20. Armetheon
  21. Asahi Kasei Pharma
  22. Astellas Pharma
  23. AstraZeneca
  24. Aurinia Pharmaceuticals
  25. Avexxin
  26. Barclays Bank
  27. Bay City Capital
  28. Bayer
  29. Baylor College of Medicine
  30. Beijing Anzhen Hospital
  31. Bichat-Claude Bernard Hospital
  32. Bill & Melinda Gates Foundation
  33. BIOCAD
  34. BioVirtus
  35. BLR Bio
  36. Boehringer Ingelheim
  37. Boryung Pharmaceutical
  38. Bristol-Myers Squibb
  39. Calliditas Therapeutics
  40. California Institute of Renal Research
  41. Cara Therapeutics
  42. CARB-X
  43. Cash Capital
  44. Cedars-Sinai Medical Center 
  45. Cellmid 
  46. Celgene
  47. Centre Hospitalier Universitaire
  48. China Medical University Hospital
  49. Children's Mercy Hospital
  50. ChemoCentryx
  51. Chugai Pharmaceutical
  52. Clough Capital 
  53. Complexa
  54. Concert Pharmaceuticals
  55. Cormorant Asset Management
  56. Cowen Healthcare Investments
  57. Cowin Capital Group
  58. Creighton University
  59. CTI Life Sciences Fund
  60. CuraGen 
  61. Cycad Group
  62. Daiichi Sankyo
  63. DaVita Clinical Research 
  64. Sumitomo Dainippon Pharma 
  65. DiaMedica Therapeutics
  66. Dimerix
  67. Dong-A ST
  68. Dongguk University
  69. Duke University 
  70. Dynavax Technologies
  71. Eastern Capital
  72. EcoR1 Capital
  73. Edmond de Rothschild Investment Partners
  74. Efung Capital
  75. Ege University
  76. ElexoPharm
  77. Eli Lilly and Company
  78. Elite Capital
  79. Ember Therapeutics
  80. Epidarex Capital
  81. Epigen Biosciences
  82. Espero BioPharma
  83. Evanston Northwestern Hospital
  84. Evotec
  85. Flagship Pioneering
  86. Foresee Pharmaceuticals
  87. F-Prime Capital Partners
  88. Fresenius Medical Care
  89. Fudan University
  90. Galencia
  91. Galectin Therapeutics
  92. Gazi University
  93. Gabriele d’Annunzio’ University
  94. Genentech
  95. Genexine
  96. Genkyotex
  97. Georgetown University
  98. George Washington University
  99. Gilead Sciences
  100. GlaxoSmithKline
  101. Glycadia Pharmaceuticals
  102. GNI Group 
  103. Goldfinch Bio
  104. Goldman Sachs
  105. Gujarat Kidney Foundation
  106. Hadassah Medical Center
  107. Hamad Medical
  108. H.C. Wainwright
  109. Hanmi Pharmaceutical
  110. Hansa Medical
  111. HBM Healthcare Investments
  112. Hennepin Healthcare 
  113. Heidelberg University
  114. Hercules Capital 
  115. Hermed Capital
  116. Hoffmann-La Roche
  117. Hospital Aleman
  118. Human Genome Sciences 
  119. Hydra Biosciences
  120. Icahn School of Medicine at Mount Sinai 
  121. Idera Pharmaceuticals
  122. Indiana University
  123. Innovation Network Corporation of Japan
  124. Inositec 
  125. inRegen
  126. Inselspital
  127. Ionis Pharmaceuticals
  128. Iran University of Medical Sciences
  129. Ironwood Pharmaceuticals
  130. Italian Hospital 
  131. JAFCO 
  132. Janssen Pharmaceuticals 
  133. Japan Tobacco International
  134. Jiangsu Maslech Medical Technology
  135. Johns Hopkins University
  136. JPMorgan Chase
  137. Kadmon 
  138. KAI Pharmaceuticals
  139. KBP Biosciences
  140. Keryx Biopharmaceuticals
  141. Kezar Life Sciences
  142. King's College London
  143. KISSEI Pharmaceutical
  144. Klotho Therapeutics
  145. Knight Therapeutics
  146. Konkuk University
  147. Korea Investment Partners
  148. Kyowa Hakko Kirin
  149. Kyung Hee University
  150. L&F Research
  151. La Jolla Pharmaceutical
  152. Lanthio Pharma
  153. Lawson Health Research Institute
  154. LCR Clinical Research
  155. Lexicon Pharmaceuticals
  156. LG Life Sciences
  157. Limulus Venture Partners
  158. London Health Sciences Centre
  159. Longitude Capital
  160. Lonza
  161. Mallinckrodt Pharmaceuticals
  162. Mannkind Corporation
  163. Mariel Therapeutics
  164. Maruishi Pharmaceutical 
  165. Massachusetts General Hospital
  166. Mayo Clinic
  167. McMaster University
  168. Medicxi Ventures
  169. MedImmune
  170. Medical University of Graz
  171. Medipal Holdings
  172. Medison Pharma
  173. Megapharm
  174. Merck Serono
  175. Merck Sharp & Dohme
  176. Michigan State University
  177. Mission Therapeutics
  178. Mitsubishi Tanabe Pharma
  179. Morningside Ventures
  180. MRL Ventures Fund
  181. National Taiwan University Hospital
  182. Nephrotic Syndrome Study Network
  183. New Enterprise Associates 
  184. Necker-Enfants Malades Hospital
  185. NorthShore University HealthSystem
  186. Novadiol
  187. Novartis Institutes for Biomedical Research
  188. Novartis Pharmaceuticals
  189. Novo Nordisk
  190. NOXXON Pharma
  191. Omega Funds
  192. OPKO Health
  193. Orange County Research Center
  194. Oraxion Therapeutics
  195. OrbiMed
  196. Orbis Biosciences
  197. Oregon Health & Science University
  198. Ottawa Hospital Research Institute
  199. Otsuka Pharmaceuticals
  200. Oxford Finance 
  201. University of Oxford 
  202. Palladio Biosciences
  203. Pappas Ventures
  204. Paranta Biosciences
  205. Pfizer
  206. Pfizer Venture Investments
  207. Pharmacosmos
  208. Ping An Ventures
  209. PKD Foundation
  210. Polaris Partners
  211. Prometic Life Sciences
  212. Proteomics International
  213. Proteon Therapeutics
  214. Qiming Venture Partners
  215. Queen Mary’s Hospital 
  216. Reata Pharmaceuticals
  217. Redx Pharma
  218. Regulus Therapeutics
  219. Relypsa
  220. Resverlogix
  221. Retrophin
  222. Rigel Pharmaceuticals
  223. Roche
  224. Rockwell Medical
  225. UC San Diego School of Medicine
  226. Sahlgrenska University Hospital
  227. Sandoz
  228. Sangel Capital
  229. Sanifit
  230. Sanofi
  231. SCOHIA PHARMA
  232. SDIC Venture Capital
  233. Sectoral Asset Management
  234. Seoul National University
  235. Seoul St. Mary's Hospital
  236. Serodus
  237. Serum Institute of India
  238. Severance Hospital 
  239. St. George's University
  240. Fosun Pharma
  241. Samsung Medical Center
  242. Shenyang Sunshine Pharmaceutical
  243. Shenzhen Hepalink Pharmaceutical
  244. Shield Therapeutics
  245. Sibling Capital Ventures 
  246. Silicon Valley Bank
  247. Silver Creek Pharmaceuticals 
  248. SK Group
  249. Sofinnova Ventures
  250. Stanford University
  251. Taipei Medical University
  252. Taisho Pharmaceutical
  253. Takeda Pharmaceuticals
  254. Teijin Pharma
  255. Tel Aviv Sourasky Medical Center
  256. The Medical University of South Carolina
  257. Toronto General Hospital
  258. Theravance Biopharma
  259. The George Institute for Global Health 
  260. The Rogosin Institute
  261. Third Rock Ventures
  262. Thynk Capital
  263. Tokai University
  264. Trevi Therapeutics
  265. Tricida
  266. Trisaq
  267. TR-Pharm
  268. Tufts Medical Center
  269. UnicoCell Biomed
  270. Unicyte
  271. The University of Alabama
  272. University Hospitals Birmingham
  273. The University of British Columbia
  274. University of California
  275. University of Calgary
  276. University of Cincinnati
  277. University of Frankfurt
  278. University of Giessen
  279. University of Guadalajara
  280. University of Illinois
  281. University of Kentucky
  282. University of Leeds
  283. University of Louisville
  284. University of Manitoba
  285. University of Maryland
  286. University of Michigan
  287. University of Minnesota
  288. University of Missouri
  289. University of North Carolina
  290. University of Oklahoma
  291. University Hospital Center De Montpellier
  292. University of Montreal
  293. University of Pennsylvania
  294. University of Ulsan
  295. University of Utah 
  296. University of Wisconsin 
  297. University Hospital Bonn
  298. Uppsala University Hospital
  299. University of Zurich
  300. Vanderbilt University Medical Center 
  301. Variant Pharmaceuticals
  302. venBio Global Strategic Fund
  303. venBio Select
  304. Venrock Healthcare Capital Partners 
  305. Verily Life Sciences
  306. Vertex Venture Holdings
  307. Vidasym
  308. Vifor Fresenius Medical Care Renal Pharma
  309. Vifor Pharma
  310. Visterra
  311. Vivo Capital
  312. Washington University School of Medicine
  313. Watson Laboratories
  314. Wellington Management 
  315. XORTX Therapeutics
  316. Yuhan Corporation
  317. Zeria Pharmaceutical
  318. ZS Pharma

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.